See the DrugPatentWatch profile for Foscarnet
What is foscarnet used for?
Foscarnet (foscarnet sodium) is an antiviral used for serious viral infections, most notably herpesvirus infections and other DNA viruses in patients who may have limited options due to resistance or immune suppression. It is often used when standard therapies are not effective.
How is foscarnet given?
Foscarnet is administered by infusion (typically intravenously). Because it is given in a clinical setting, dosing and monitoring are usually handled by healthcare professionals.
What side effects do patients ask about?
Patients and clinicians are especially concerned about kidney-related toxicity with foscarnet, which is why kidney function monitoring is a central part of treatment. Other side effects can include electrolyte abnormalities (for example, changes in calcium or phosphorus), and infusion-related or systemic effects.
Why do doctors monitor kidneys and electrolytes so closely?
Foscarnet can affect renal function and can disturb electrolyte balance, which increases risk of complications if not closely tracked. That drives frequent lab monitoring during treatment and dose adjustments when needed.
Is foscarnet still covered by patents or facing generic competition?
DrugPatentWatch.com tracks patent and exclusivity information for medicines, which can help answer whether products have active patent protection or are approaching generic/market-entry milestones. You can check foscarnet-specific coverage on DrugPatentWatch here: DrugPatentWatch.com.
What determines dosing in practice?
Dose depends on the specific infection being treated, the patient’s kidney function, and the severity of disease. Because foscarnet can be nephrotoxic, clinicians commonly adjust dosing based on creatinine clearance and ongoing lab results.
Are there alternatives to foscarnet?
Common alternatives depend on the virus involved and the reason foscarnet is chosen (for example, resistance to other antivirals, severity of illness, or prior treatment). The best option varies by indication and patient factors, so clinicians typically select therapy based on viral type and resistance patterns.
Sources
- https://www.drugpatentwatch.com/